%0 Journal Article %A Asiye Büsra Çimen %A Ayşe Füsun Kalpaklıoğlu %T Comparison of acute phase reactant pentraksin-3 and inflammatory parameters in acute and stable pulmonary embolism %D 2021 %R 10.1183/13993003.congress-2021.PA510 %J European Respiratory Journal %P PA510 %V 58 %N suppl 65 %X Introduction: Pulmonary thromboembolism; It is an obstructive disease of the pulmonary arterial system in different degrees and localization as a result of embolization of thrombi or non-thrombus substances. Pentraxin 3(PTX-3) is a member of the pentraxin family, in the same family as C-reactive protein. Our aim in this study reveals that the plasma PTX-3 level in PTE patients may be closely related to the prognosis of the disease as well as the diagnosis of PTE.Method: At the time of diagnosis, demographical characteristics and lab findings after 3 months of antikoagulant treatment have been saved of the patients that been studied. 5 cc plasma was taken from the patients who participated in the study at the time of diagnosis and from the 3rd month routine controls and from the control group for PTX-3 study and stored at -80 degrees.Findings: From a total of 74 patients in accordance with the study protocol( 50 patients;24 control group). From the patients who used anticoagulants for 3 months, 35 patients came for the second visit, 4 died, 11 patients left the study. A meaningful increase in PTX-3 levels was detected in the patient group(0.46 ng/ml) compared to the control group (0.21 ng/ml)( p;0.050).There was no meaningful change in PTX-3 levels when comparing the results at the first diagnosis with the control results performed after the 3rd month of the patients diagnosed with PTE.Conclusion: It shows that a significant increase in PTX-3 level in the patient group compared to the control group, which have proven usefulness and prognostic significance in the diagnosis of PTE at the time of theinitial diagnosis, could be helpful on diagnosis in situations that PTE suspectedFootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA510.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). %U